Christopher Ogden sold $33k of CTMX
Chief Financial Officer at CytomX Therapeutics, Inc.. 12,255 shares at an average of $2.72, traded Jun 13, 2025, filed Jun 17, 2025.
Score components
- +22RoleCFO
- +6Trade size$33k at market
- 0Share of holdings soldSold 6.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-25-000236, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 13, 2025 | SOpen-market sale Common Stock | -1,641 | $2.95 | $4,841 | 199,385 | Jun 17, 2025 |
| Jun 13, 2025 | MOption exercise Common Stock | +37,500 | $0.00 | $0 | 236,885 | Jun 17, 2025 |
| Jun 16, 2025 | SOpen-market sale Common Stock | -10,614 | $2.69 | $29k | 226,271 | Jun 17, 2025 |
| Jun 13, 2025 | MOption exercise Performance Stock Unitsderivative | -37,500 | $0.00 | $0 | 0 | Jun 17, 2025 |
Related signals
Other insiders at CytomX Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | CTMXsell CytomX Therapeutics, Inc. | Christopher Ogden Chief Financial Officer | $4,953 1,624 shares | -1% | |
| 42Moderate | CytomX Therapeutics, Inc. | Marcia Belvin SVP, Chief Scientific Officer | $202k 31,492 shares | -9% | |
| 46Moderate | CytomX Therapeutics, Inc. | Yu-Waye Chu Chief Medical Officer | $137k 21,279 shares | -10% | |
| 47Moderate | CytomX Therapeutics, Inc. | Christopher Ogden Chief Financial Officer | $124k 19,323 shares | -6% | |
| 42Moderate | CytomX Therapeutics, Inc. | Sean A. McCarthy CEO | $764k 118,969 shares | -10% | |
| 22Weak | CytomX Therapeutics, Inc. | Sean A. McCarthy CEO | $462k 101,793 shares | -9% | |
| 21Weak | CytomX Therapeutics, Inc. | Marcia Belvin SVP, Chief Scientific Officer | $37k 13,884 shares | -5% | |
| 36Weak | CytomX Therapeutics, Inc. | Sean A. McCarthy CEO | $149k 55,511 shares | -5% | |
| 30Weak | CytomX Therapeutics, Inc. | Marcia Belvin SVP, Chief Scientific Officer | $12k 19,512 shares | -7% | |
| 30Weak | CytomX Therapeutics, Inc. | Yu-Waye Chu Chief Medical Officer | $2,411 4,025 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.